Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany (Q42281395)

19 October 2017

title

Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany (English)

1 reference

19 October 2017

0 references

1 reference

8

1 reference

19 October 2017

Gérard Krause

5

0 references

author name string

Bernhard Ultsch

1

1 reference

19 October 2017

Ingrid Köster

2

1 reference

19 October 2017

Thomas Reinhold

3

1 reference

19 October 2017

Anette Siedler

4

1 reference

19 October 2017

Andrea Icks

6

1 reference

19 October 2017

Ingrid Schubert

7

1 reference

19 October 2017

language of work or name

1 reference

28 December 2012

1 reference

The European Journal of Health Economics

19 October 2017

published in

1 reference

19 October 2017

volume

14

1 reference

19 October 2017

issue

6

1 reference

19 October 2017

page(s)

1015-1026

1 reference

Seroprevalence of varicella-zoster virus in the German population

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Sample survey of persons insured in statutory health insurance institutions in Hessen--concept and realisation of person-related data base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

GPS--good practice secondary data analysis. Working Group for the Survey and Utilization of Secondary Data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster in Germany: quantifying the burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster guideline of the German Dermatology Society (DDG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster: Burden of disease in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Amitriptyline, but not lorazepam, relieves postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Pain and its persistence in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Post-shingles neuralgia by any definition is painful, but is it PHN?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

A decision chart for assessing and improving the transferability of economic evaluation results between countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

The incidence of herpes zoster in a United States administrative database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

The burden of Herpes Zoster: a prospective population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Diabetes prevalence based on health insurance claims: large differences between companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Implementation of the new German job role code and its application in claims data analysis. Possibilities and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

Work and Health. Representative work-related health monitoring with sickness absence data of the company health insurance in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-012-0452-1

A Prospective Study of the Herpes Zoster Severity of Illness

21 January 2018

1 reference

12 December 2020

Treatment of herpes zoster.

1 reference

12 December 2020

THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS

1 reference

12 December 2020

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years

1 reference

12 December 2020

[Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation]

1 reference

12 December 2020

Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.

1 reference

12 December 2020

Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database

1 reference

12 December 2020

Varicella zoster virus: natural history and current therapies of varicella and herpes zoster

1 reference

12 December 2020

The incidence of herpes zoster

1 reference

12 December 2020

Postherpetic neuralgia

1 reference

12 December 2020

Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system?

1 reference

12 December 2020

Herpes zoster in Germany. A retrospective analyse of SHL data

1 reference

12 December 2020

10.1007/S10198-012-0452-1

Identifiers

DOI

1 reference

19 October 2017

1 reference